Skip to main content
PMC home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1991 Jan 15;144(2):153–158.

Clinical uses of gonadotropin-releasing hormone analogues.

R F Casper 1
PMCID: PMC1452955  PMID: 1986827

Abstract

Gonadotropin-releasing hormone (Gn-RH) analogues are synthetic derivatives of the native hypothalamic peptide with alterations in their chemical structure that result in changes in biologic activity. Several Gn-RH agonists are available for clinical use, and all act through the same mechanism: first to stimulate and then to inhibit gonadotropin and gonadal steroid secretion by downregulating the pituitary Gn-RN receptors. This review should provide clinicians with a working knowledge of the physiologic and pharmacokinetic features of Gn-RH agonists. Although over 2000 articles concerning Gn-RH analogues have been published I chose to review only those that were the first to report a novel clinical application. Gn-RH agonists have proved to be extremely efficacious in treating gonadal steroid-dependent problems such as endometriosis, uterine leiomyoma, precocious puberty and prostate and breast cancers, and they have resulted in very few side effects. Long-term use may, however, lead to skeletal calcium loss in women as a consequence of hypoestrogenism. Further research is needed to prevent this and maintain clinical efficacy.

Full text

PDF
154

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Awadalla S. G., Friedman C. I., Chin N. W., Dodds W., Park J. M., Kim M. H. Follicular stimulation for in vitro fertilization using pituitary suppression and human menopausal gonadotropins. Fertil Steril. 1987 Nov;48(5):811–815. doi: 10.1016/s0015-0282(16)59536-3. [DOI] [PubMed] [Google Scholar]
  2. Belaisch-Allart J., Testart J., Frydman R. Utilization of GnRH agonists for poor responders in an IVF programme. Hum Reprod. 1989 Jan;4(1):33–34. doi: 10.1093/oxfordjournals.humrep.a136840. [DOI] [PubMed] [Google Scholar]
  3. Casper R. F., Sheehan K. L., Yen S. S. Gonadotropin-estradiol responses to a superactive luteinizing hormone-releasing hormone agonist in women. J Clin Endocrinol Metab. 1980 Jan;50(1):179–181. doi: 10.1210/jcem-50-1-179. [DOI] [PubMed] [Google Scholar]
  4. Chang R. J., Laufer L. R., Meldrum D. R., DeFazio J., Lu J. K., Vale W. W., Rivier J. E., Judd H. L. Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist. J Clin Endocrinol Metab. 1983 May;56(5):897–903. doi: 10.1210/jcem-56-5-897. [DOI] [PubMed] [Google Scholar]
  5. Comite F., Cassorla F., Barnes K. M., Hench K. D., Dwyer A., Skerda M. C., Loriaux D. L., Cutler G. B., Jr, Pescovitz O. H. Luteinizing hormone releasing hormone analogue therapy for central precocious puberty. Long-term effect on somatic growth, bone maturation, and predicted height. JAMA. 1986 May 16;255(19):2613–2616. [PubMed] [Google Scholar]
  6. Couzinet B., Le Strat N., Brailly S., Schaison G. Comparative effects of cyproterone acetate or a long-acting gonadotropin-releasing hormone agonist in polycystic ovarian disease. J Clin Endocrinol Metab. 1986 Oct;63(4):1031–1035. doi: 10.1210/jcem-63-4-1031. [DOI] [PubMed] [Google Scholar]
  7. Crowley W. F., Jr, Comite F., Vale W., Rivier J., Loriaux D. L., Cutler G. B., Jr Therapeutic use of pituitary desensitization with a long-acting lhrh agonist: a potential new treatment for idiopathic precocious puberty. J Clin Endocrinol Metab. 1981 Feb;52(2):370–372. doi: 10.1210/jcem-52-2-370. [DOI] [PubMed] [Google Scholar]
  8. Damewood M. D., Schlaff W. D., Hesla J. S., Rock J. A. Interval bone mineral density with long-term gonadotropin-releasing hormone agonist suppression. Fertil Steril. 1989 Oct;52(4):596–599. doi: 10.1016/s0015-0282(16)60970-6. [DOI] [PubMed] [Google Scholar]
  9. Dlugi A. M., Rufo S., D'Amico J. F., Seibel M. M. A comparison of the effects of Buserelin versus danazol on plasma lipoproteins during treatment of pelvic endometriosis. Fertil Steril. 1988 May;49(5):913–916. doi: 10.1016/s0015-0282(16)59906-3. [DOI] [PubMed] [Google Scholar]
  10. Filicori M., Hall D. A., Loughlin J. S., Rivier J., Vale W., Crowley W. F., Jr A conservative approach to the management of uterine leiomyoma: pituitary desensitization by a luteinizing hormone-releasing hormone analogue. Am J Obstet Gynecol. 1983 Nov 15;147(6):726–727. doi: 10.1016/0002-9378(83)90463-5. [DOI] [PubMed] [Google Scholar]
  11. Fisher E. C., Nelson M. E., Frontera W. R., Turksoy R. N., Evans W. J. Bone mineral content and levels of gonadotropins and estrogens in amenorrheic running women. J Clin Endocrinol Metab. 1986 Jun;62(6):1232–1236. doi: 10.1210/jcem-62-6-1232. [DOI] [PubMed] [Google Scholar]
  12. Friedman A. J., Barbieri R. L., Benacerraf B. R., Schiff I. Treatment of leiomyomata with intranasal or subcutaneous leuprolide, a gonadotropin-releasing hormone agonist. Fertil Steril. 1987 Oct;48(4):560–564. [PubMed] [Google Scholar]
  13. Fujino M., Lobayashi S., Obayashi M., Shinagawa S., Fukuda T. Structure-activity relationships in the C-terminal part of luteinizing hormone releasing hormone(LH-RH). Biochem Biophys Res Commun. 1972 Nov 1;49(3):863–869. doi: 10.1016/0006-291x(72)90490-1. [DOI] [PubMed] [Google Scholar]
  14. Gulyas B. J., Matsuura S., Chen H. C., Yuan L. C., Hodgen G. D. Visualization of binding and internalization of a horseradish peroxidase-hCG conjugate by monkey luteal cells. Biol Reprod. 1981 Oct;25(3):609–620. doi: 10.1095/biolreprod25.3.609. [DOI] [PubMed] [Google Scholar]
  15. Henzl M. R., Corson S. L., Moghissi K., Buttram V. C., Berqvist C., Jacobson J. Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. N Engl J Med. 1988 Feb 25;318(8):485–489. doi: 10.1056/NEJM198802253180805. [DOI] [PubMed] [Google Scholar]
  16. Kaufmann M., Jonat W., Kleeberg U., Eiermann W., Jänicke F., Hilfrich J., Kreienberg R., Albrecht M., Weitzel H. K., Schmid H. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group. J Clin Oncol. 1989 Aug;7(8):1113–1119. doi: 10.1200/JCO.1989.7.8.1113. [DOI] [PubMed] [Google Scholar]
  17. Klijn J. G., de Jong F. H. Treatment with a luteinising-hormone-releasing-hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer. Lancet. 1982 May 29;1(8283):1213–1216. doi: 10.1016/s0140-6736(82)92339-x. [DOI] [PubMed] [Google Scholar]
  18. Knobil E. The neuroendocrine control of the menstrual cycle. Recent Prog Horm Res. 1980;36:53–88. doi: 10.1016/b978-0-12-571136-4.50008-5. [DOI] [PubMed] [Google Scholar]
  19. Luder A. S., Holland F. J., Costigan D. C., Jenner M. R., Wielgosz G., Fazekas A. T. Intranasal and subcutaneous treatment of central precocious puberty in both sexes with a long-acting analog of luteinizing hormone-releasing hormone. J Clin Endocrinol Metab. 1984 Jun;58(6):966–972. doi: 10.1210/jcem-58-6-966. [DOI] [PubMed] [Google Scholar]
  20. Macnamee M. C., Howles C. M., Edwards R. G. Pregnancies after IVF when high tonic LH is reduced by long-term treatment with GnRH agonists. Hum Reprod. 1987 Oct;2(7):569–571. doi: 10.1093/oxfordjournals.humrep.a136590. [DOI] [PubMed] [Google Scholar]
  21. Maheux R., Guilloteau C., Lemay A., Bastide A., Fazekas A. T. Regression of leiomyomata uteri following hypoestrogenism induced by repetitive luteinizing hormone-releasing hormone agonist treatment: preliminary report. Fertil Steril. 1984 Oct;42(4):644–646. doi: 10.1016/s0015-0282(16)48152-5. [DOI] [PubMed] [Google Scholar]
  22. Manasco P. K., Pescovitz O. H., Feuillan P. P., Hench K. D., Barnes K. M., Jones J., Hill S. C., Loriaux D. L., Cutler G. B., Jr Resumption of puberty after long term luteinizing hormone-releasing hormone agonist treatment of central precocious puberty. J Clin Endocrinol Metab. 1988 Aug;67(2):368–372. doi: 10.1210/jcem-67-2-368. [DOI] [PubMed] [Google Scholar]
  23. Marian J., Conn P. M. The calcium requirement in GnRH-stimulated LH release is not mediated through a specific action on receptor binding. Life Sci. 1980 Jul 7;27(1):87–92. doi: 10.1016/0024-3205(80)90022-3. [DOI] [PubMed] [Google Scholar]
  24. Matta W. H., Stabile I., Shaw R. W., Campbell S. Doppler assessment of uterine blood flow changes in patients with fibroids receiving the gonadotropin-releasing hormone agonist Buserelin. Fertil Steril. 1988 Jun;49(6):1083–1085. doi: 10.1016/s0015-0282(16)59966-x. [DOI] [PubMed] [Google Scholar]
  25. Meldrum D. R., Chang R. J., Lu J., Vale W., Rivier J., Judd H. L. "Medical oophorectomy" using a long-acting GNRH agonist--a possible new approach to the treatment of endometriosis. J Clin Endocrinol Metab. 1982 May;54(5):1081–1083. doi: 10.1210/jcem-54-5-1081. [DOI] [PubMed] [Google Scholar]
  26. Miller W. R., Scott W. N., Morris R., Fraser H. M., Sharpe R. M. Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature. 1985 Jan 17;313(5999):231–233. doi: 10.1038/313231a0. [DOI] [PubMed] [Google Scholar]
  27. Monahan M. W., Amoss M. S., Anderson H. A., Vale W. Synthetic analogs of the hypothalamic luteinizing hormone releasing factor with increased agonist or antagonist properties. Biochemistry. 1973 Nov 6;12(23):4616–4620. doi: 10.1021/bi00747a012. [DOI] [PubMed] [Google Scholar]
  28. Muse K. N., Cetel N. S., Futterman L. A., Yen S. C. The premenstrual syndrome. Effects of "medical ovariectomy". N Engl J Med. 1984 Nov 22;311(21):1345–1349. doi: 10.1056/NEJM198411223112104. [DOI] [PubMed] [Google Scholar]
  29. Parmar H., Phillips R. H., Lightman S. L., Edwards L., Allen L., Schally A. V. Randomised controlled study of orchidectomy vs long-acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinoma. Lancet. 1985 Nov 30;2(8466):1201–1205. doi: 10.1016/s0140-6736(85)90739-1. [DOI] [PubMed] [Google Scholar]
  30. Redding T. W., Schally A. V. Inhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A. 1983 Mar;80(5):1459–1462. doi: 10.1073/pnas.80.5.1459. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Riis B., Thomsen K., Christiansen C. Does calcium supplementation prevent postmenopausal bone loss? A double-blind, controlled clinical study. N Engl J Med. 1987 Jan 22;316(4):173–177. doi: 10.1056/NEJM198701223160401. [DOI] [PubMed] [Google Scholar]
  32. Schlaff W. D., Zerhouni E. A., Huth J. A., Chen J., Damewood M. D., Rock J. A. A placebo-controlled trial of a depot gonadotropin-releasing hormone analogue (leuprolide) in the treatment of uterine leiomyomata. Obstet Gynecol. 1989 Dec;74(6):856–862. [PubMed] [Google Scholar]
  33. Steingold K., De Ziegler D., Cedars M., Meldrum D. R., Lu J. K., Judd H. L., Chang R. J. Clinical and hormonal effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovarian disease. J Clin Endocrinol Metab. 1987 Oct;65(4):773–778. doi: 10.1210/jcem-65-4-773. [DOI] [PubMed] [Google Scholar]
  34. Tolis G., Ackman D., Stellos A., Mehta A., Labrie F., Fazekas A. T., Comaru-Schally A. M., Schally A. V. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci U S A. 1982 Mar;79(5):1658–1662. doi: 10.1073/pnas.79.5.1658. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Tummon I. S., Ali A., Pepping M. E., Radwanska E., Binor Z., Dmowski W. P. Bone mineral density in women with endometriosis before and during ovarian suppression with gonadotropin-releasing hormone agonists or danazol. Fertil Steril. 1988 May;49(5):792–796. [PubMed] [Google Scholar]
  36. Välimäki M., Nilsson C. G., Roine R., Ylikorkala O. Comparison between the effects of nafarelin and danazol on serum lipids and lipoproteins in patients with endometriosis. J Clin Endocrinol Metab. 1989 Dec;69(6):1097–1103. doi: 10.1210/jcem-69-6-1097. [DOI] [PubMed] [Google Scholar]
  37. de Ziegler D., Steingold K., Cedars M., Lu J. K., Meldrum D. R., Judd H. L., Chang R. J. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease. J Clin Endocrinol Metab. 1989 Jun;68(6):1111–1117. doi: 10.1210/jcem-68-6-1111. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES